Granules India had received advise from the EU Health authorities to test for the presence of NDMA in metformin manufactured by the company. Granules had done a thorough risk assessment based on the route of synthesis used by it and had come to the conclusion that there is no possibility of the presence of NDMA in its product. This was informed to the EU authorities.
However the product is under analytical testing and preliminary results have shown that the impurity is absent. Further testing is ongoing and Granules will keep the EU authority updated.
Shares of GRANULES INDIA LTD. was last trading in BSE at Rs.126.7 as compared to the previous close of Rs. 127.55. The total number of shares traded during the day was 35598 in over 946 trades.
The stock hit an intraday high of Rs. 128.05 and intraday low of 125.9. The net turnover during the day was Rs. 4519805.